Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q3 FY2023 Earnings Presentation
22 slides from Rossari Biotech's earnings presentation, Feb 5, 2023
Slide 1: Rossari – Earnings Presentation Filing Letter
® ROSSARI making you more competitive February 05, 2023 DCS-CRD Listing Compliance BSELimited National Stock Exchange of IndiaLtd. First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No.C/1, 'G'Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai
Slide 2: Rossari Biotech Limited Q3 & 9M FY23 Results Presentation
Rossari Biotech Limited Q3 & 9M FY23 Results Presentation February 4, 2023
Slide 3: Disclaimer
Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward-looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to b
Slide 4: Q3 & 9M FY23 Results Overview
Q3 & 9M FY23 Results Overview 3
Slide 5: Q3 FY23 – Key Financial Highlights
Q3 FY23 – Key Financial Highlights Revenue from Operations EBITDA PAT (Rs. crore) (Rs. crore) (Rs. crore) 425.4 428.4 56.5 25.7 54.2 23.9 389.3 47.7 22.5 Q3 FY23 Q2 FY23 Q3 FY22 Q3 FY23 Q2 FY23 Q3 FY22 Q3 FY23 Q2 FY23 Q3 FY22 Shift % (Y-o-Y) -9.1% 13.4% 13.9% Shift % (Q-o-Q) -8.5% -4.2% 7.4% Margins
Slide 6: Management Message
Management Message Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We have reported a stable performance during the quarter despite the ongoing challenging operating environment. All our
Slide 7: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated Y-o-Y Y-o-Y Particulars (Rs. crore) Q3 FY23 Q3 FY22 Change 9M FY23 9M FY22 Change (%) (%) Revenues from Operations 389.3 428.4 -9.1% 1249.4 1044.0 19.7% Total Expenditure • COGS 272.4 322.4 -15.5% 885.1 782.8 13.1% • Employee benefits expense 24.2 20.2 19.8% 71.
Slide 8: Q3 FY23 - Segment-wise Details
Q3 FY23 - Segment-wise Details Segment-wise Revenue Break-up (Rs. crore) Q3 FY23 Q2 FY23 Q3 FY22 303.85 293.95 271.17 110.64 89.46 91.39 28.64 30.2 23.83 HPPC TSC AHN Shift (Y-o-Y) % -7.7% -19.2% 20.2% Shift (Q-o-Q) % -10.8% -2.1% -5.2% Note: 1) All figures, unless mentioned otherwise, are on a cons
Slide 9: Q3 FY23 - Financial and Operational Discussions
Q3 FY23 - Financial and Operational Discussions Net Revenues Q3 FY23 Revenues from operations stood at Rs. 389.3 crore Subsidiaries witnessed a slowdown leading to lower consolidated revenues • Textile and AHN segments reported stable performance during the quarter, while HPPC witnessed subdued de
Slide 10: Company Overview
Company Overview 9
Slide 11: Rossari – At a Glance
Rossari – At a Glance Technocrat promoters with 45+ 8* 354,100* 4* 57% 22% cumulative years of Manufacturing MTPA Revenue CAGR % PAT CAGR % experience in the R&D Facilities facilities Capacity Installed (FY19-22) (FY19-22) specialty chemicals industry Rossari – A Specialty-Chemical manufacturer prov
Slide 12: Business Overview
Business Overview One of the leading specialty chemicals manufacturer delivering differentiated & tailor-made solutions across Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC) and Animal Health and Nutrition (AHN) businesses HPPC TSC AHN One of the fastest-gr
Slide 13: Strengthening Market Presence
Strengthening Market Presence Growing client base Diversifying of over 1,000 customer base to customers both lower India and concentration risk International Widening Increasingly tapping distribution new segments across network to drive domestic and reach international markets Company’s focus towar
Slide 14: Robust Manufacturing Capabilities
Robust Manufacturing Capabilities Located on 8.6 acres of land Manufacturing Fungible manufacturing capabilities for powders, granules and liquids Facility at Facility has a comprehensive range of testing & packaging capabilities Silvassa Effluent treatment facility, with 2,500 MT bulk stora
Slide 15: Strategic Growth Levers
Strategic Growth Levers Augmenting product portfolio with enhanced emphasis on green solutions Increase wallet share across existing customer base while also tapping new customer segments Identifying and developing new niches in product offerings by leveraging R&D capabilities Capitalize on cros
Slide 16: Recent Inorganic Initiatives
Recent Inorganic Initiatives Executed two synergistic acquisitions and one strategic investment in FY 2022 complementing the ethos of Rossari’s business model SF Unitop Chemicals Tristar Intermediates Romakk Chemicals Prominent player in the field of Preservatives, Primarily engaged in the business
Slide 17: Key Synergies from Recent Acquisitions
Key Synergies from Recent Acquisitions Strategic & value-accretive acquisitions accelerate growth and drive economies of scale Augmented Pooling together Expansion of of related Inorganic presence in Extension of addressable technologies investments Specialty manufacturing domestic and within operat
Slide 18: Focus on Green & Sustainable Chemical Solutions
Focus on Green & Sustainable Chemical Solutions Specialists in producing environmentally- benign substitutes that replace legacy and harmful products Focus on green, sustainable and cost neutral products Minimizing carbon footprint of manufacturing processes while maximizing customer benefits Aggres
Slide 19: Annexure
ROSSARI making you more competitive Annexure 18
Slide 20: Conference Call Details
Conference Call Details Q3 FY23 Earnings Conference Call Time • 3:30 p.m. IST on Monday, February 6, 2022 To enable participants to connect to the conference call without Pre-registration having to wait for an operator, please register at the below mentioned link: Primary dial-in number • + 91 22 62
Slide 21: About Us
About Us Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a For further information, please contact: Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Manasi Nisal Headquartered at Mumbai, India, the Company operates Ro
Slide 22: Thank you
Thank y#u making you more competitive